[Severe Raynaud's phenomenon associated with interferon-beta 1a and fluoxetine].
De Broucker
T
T
Service de Neurologie, Hôpital Delafontaine, Saint-Denis.
Lhote
F
F
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D016285:Iloprost / Q000627:therapeutic use; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000009:adverse effects*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications / Q000188:drug therapy; D011928:Raynaud Disease / Q000139:chemically induced* / Q000188:drug therapy; D014665:Vasodilator Agents / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000925:Anticoagulants; D018687:Antidepressive Agents, Second-Generation; D014665:Vasodilator Agents; D005473:Fluoxetine; D016899:Interferon-beta; D006493:Heparin; D016285:Iloprost; D000068556:Interferon beta-1a